Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julien Seneschal

Showing results (121-130 of 182) with videos related to

Pageof 19
Sort By:
The Journal of Investigative Dermatology|September 21, 2017
Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3Katia Boniface, Clément Jacquemin, Anne-Sophie Darrigade, et al.
Trials|July 23, 2022
Vitiligo International Task force for an Agreed List of core data (VITAL): study protocol of a vitiligo core outcome set (COS) and contextual factors for clinical trials, registries, and clinical practiceNanja van Geel, Iltefat H Hamzavi, Amit G Pandya, et al.
Science Translational Medicine|September 3, 2010
Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosusPierre Duffau, Julien Seneschal, Carole Nicco, et al.
The New England Journal of Medicine|October 19, 2022
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for VitiligoDavid Rosmarin, Thierry Passeron, Amit G Pandya, et al.
American Journal of Clinical Dermatology|March 14, 2025
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 YearsRaj Chovatiya, Simone Ribero, Andreas Wollenberg, et al.
The New England Journal of Medicine|March 15, 2023
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic DermatitisJonathan I Silverberg, Emma Guttman-Yassky, Diamant Thaçi, et al.
JAMA Dermatology|November 10, 2021
Evaluation of Thalidomide Treatment of Patients With Chronic Erythema Multiforme: A Multicenter Retrospective Cohort StudyCamille Roux, Emilie Sbidian, Jean-David Bouaziz, et al.
Therapeutic Advances in Chronic Disease|November 10, 2025
Treatment of vitiligo with ruxolitinib cream in the TRuE-V1 and TRuE-V2 studies: a plain language summary of publicationDavid Rosmarin, Thierry Passeron, Amit G Pandya, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 21, 2023
Clinician-reported outcome measures for the assessment of vitiligo: A scoping reviewNanja van Geel, Jolien Duponselle, Liesbeth Delbaere, et al.
JCI Insight|May 6, 2020
Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligoNesrine Boukhedouni, Christina Martins, Anne-Sophie Darrigade, et al.
Pageof 19

Showing results (121-130 of 182) with videos related to

Sort By:
Pageof 19
The Journal of Investigative Dermatology|September 21, 2017
Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3Katia Boniface, Clément Jacquemin, Anne-Sophie Darrigade, et al.
Trials|July 23, 2022
Vitiligo International Task force for an Agreed List of core data (VITAL): study protocol of a vitiligo core outcome set (COS) and contextual factors for clinical trials, registries, and clinical practiceNanja van Geel, Iltefat H Hamzavi, Amit G Pandya, et al.
Science Translational Medicine|September 3, 2010
Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosusPierre Duffau, Julien Seneschal, Carole Nicco, et al.
The New England Journal of Medicine|October 19, 2022
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for VitiligoDavid Rosmarin, Thierry Passeron, Amit G Pandya, et al.
American Journal of Clinical Dermatology|March 14, 2025
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 YearsRaj Chovatiya, Simone Ribero, Andreas Wollenberg, et al.
The New England Journal of Medicine|March 15, 2023
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic DermatitisJonathan I Silverberg, Emma Guttman-Yassky, Diamant Thaçi, et al.
JAMA Dermatology|November 10, 2021
Evaluation of Thalidomide Treatment of Patients With Chronic Erythema Multiforme: A Multicenter Retrospective Cohort StudyCamille Roux, Emilie Sbidian, Jean-David Bouaziz, et al.
Therapeutic Advances in Chronic Disease|November 10, 2025
Treatment of vitiligo with ruxolitinib cream in the TRuE-V1 and TRuE-V2 studies: a plain language summary of publicationDavid Rosmarin, Thierry Passeron, Amit G Pandya, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 21, 2023
Clinician-reported outcome measures for the assessment of vitiligo: A scoping reviewNanja van Geel, Jolien Duponselle, Liesbeth Delbaere, et al.
JCI Insight|May 6, 2020
Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligoNesrine Boukhedouni, Christina Martins, Anne-Sophie Darrigade, et al.
Pageof 19